<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335351">
  <stage>Registered</stage>
  <submitdate>8/04/2010</submitdate>
  <approvaldate>3/05/2010</approvaldate>
  <actrnumber>ACTRN12610000351011</actrnumber>
  <trial_identification>
    <studytitle>Effect of combined fish oil and coenzyme Q10 supplementation on liver fat composition, liver fat content and cardiovascular risk factors in overweight men</studytitle>
    <scientifictitle>Effect of combined fish oil and coenzyme Q10 versus placebo on hepatic triglyceride concentration in overweight men</scientifictitle>
    <utrn>U1111-1114-6507</utrn>
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>hepatic steatosis</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>4 capsules (4g) per day for 12 weeks to be consumed orally of docosahexaenoic fatty acid supplement (total dose of 1g of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] combined and 200mg of coenzyme Q10 [CoQ10]/day)</interventions>
    <comparator>4 capsules (4g) per day for 12 weeks to be consumed orally of placebo (olive oil)</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Hepatic triglyceride concentration (measured by localised proton magnetic resonance spectroscopy)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hepatic triglyceride composition (magnetic resonance spectroscopy)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>visceral adiposity (magnetic resonance imaging)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>fasting plasma triglycerides (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>cholesterol (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>High Density Lipoprotein-cholesterol (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apolipoprotein A-I (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>serum biochemistry (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>insulin (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Glycated haemoglobin (HbA1c) (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Plasma adiponectin (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>High-sensitivity C-reactive protein (blood analysis)</outcome>
      <timepoint>Baseline, 6 weeks, 12 weeks.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Fasting liver enzymes (alanine aminotransferase, ALT; aspartate aminotransferase, AST; gamma-glutamyl transferase GGT) (blood analysis)</outcome>
      <timepoint>baseline, 6 weeks, 12 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Overweight men: body mass index (BMI) greater than 25 but less than 30 with a waist circumference greater than or equal to 94cm.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>history of heart, lung or kidney disease; smoking and excess alcohol consumption; known allergy to fish or other seafood; a haemorrhagic disorder, or receiving anticoagulants and/or other drugs affecting coagulation; hepatic impairment (i.e., severe liver enzyme elevation); supplements or medications known to affect outcome measures.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>The person who will determine if a subject is eligible for inclusion in the trial will be unaware, when this decision is made, to which group the subjects will be allocated. Allocation will be done by central randomisation by computer.</concealment>
    <sequence>Eligible subjects will be randomly assigned to the docosahexaenoic acid (DHA) supplement or placebo using computer generated random numbers tables.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/06/2010</anticipatedstartdate>
    <actualstartdate>7/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>7/04/2014</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize>50</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/07/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Sydney</primarysponsorname>
    <primarysponsoraddress>East Street Lidcombe NSW 2141</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Blackmores</fundingname>
      <fundingaddress>20 Jubilee Avenue Warriewood NSW 2102</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Heart Research Institute</sponsorname>
      <sponsoraddress>7 Eliza St Newtown, NSW 2042</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To investigate whether supplementation with combined fish oil/CoQ10 alters hepatic triglyceride concentration, composition and cardiovascular risk factors in overweight men.</summary>
    <trialwebsite />
    <publication>Parker HM, OConnor HT, Keating SE, Cohn JS, Garg ML, Caterson ID, George J, Johnson NA. Efficacy of the Omega-3 Index in predicting non-alcoholic fatty liver disease in overweight and obese adults: a pilot study. British Journal of Nutrition; 2015, 114(5):780-787</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Sydney South West Area Health Service (SSWAHS) Ethics Review Committee (Royal Prince Alfred Hospital [RPAH] Zone)</ethicname>
      <ethicaddress>c/- Research Development Office
Level 3, Building 92 
Royal Prince Alfred Hospital
Missenden Road
CAMPERDOWN NSW 2050</ethicaddress>
      <ethicapprovaldate>27/05/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>21/04/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Nathan Johnson</name>
      <address>Discipline of Exercise and Sport Science Faculty of Health Sciences                 
The University of Sydney
East Street Lidcombe NSW 2141</address>
      <phone>+61 02 9351 9317</phone>
      <fax />
      <email>nathan.johnson@sydney.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Helen Parker</name>
      <address>Discipline of Exercise and Sport Science Faculty of Health Sciences                 
The University of Sydney
East Street Lidcombe NSW 2141</address>
      <phone>+61 0401834392</phone>
      <fax />
      <email>hcoo0650@uni.sydney.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Nathan Johnson</name>
      <address>Discipline of Exercise and Sport Science Faculty of Health Sciences                 
The University of Sydney
East Street Lidcombe NSW 2141</address>
      <phone>+61 02 9351 9317</phone>
      <fax />
      <email>nathan.johnson@sydney.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>